GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Insider Ownership

ADC Therapeutics (ADC Therapeutics) Insider Ownership : 3.20 % (As of Apr. 28, 2024)


View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ADC Therapeutics's insider ownership is 3.20%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ADC Therapeutics's Institutional Ownership is 0.12%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ADC Therapeutics's Float Percentage Of Total Shares Outstanding is 65.31%.

ADC Therapeutics Insider Ownership Historical Data

The historical data trend for ADC Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Insider Ownership Chart

ADC Therapeutics Historical Data

The historical data trend for ADC Therapeutics can be seen below:

2023-12-31 2024-01-31 2024-02-29 2024-03-31
Insider Ownership 3.27 3.27 3.27 3.20

ADC Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Insider Ownership
Comparable Companies
IOBT TSBX ACET HCWB ANEB XLO CLGN ATHA KZR ELTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
Website
https://www.adctherapeutics.com
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.